Shandong Xinhua Pharmaceutical Company Limited (HKG:0719)
Hong Kong · Delayed Price · Currency is HKD | Market Cap | 9.70B -1.5% |
| Revenue (ttm) | 9.78B +1.2% |
| Net Income | 248.51M -49.8% |
| EPS | 0.36 -49.9% |
| Shares Out | 696.68M |
| PE Ratio | 16.22 |
| Forward PE | 15.87 |
| Dividend | 0.17 (3.01%) |
| Ex-Dividend Date | Jul 10, 2026 |
| Volume | 1,091,000 |
| Open | 5.68 |
| Previous Close | 5.71 |
| Day's Range | 5.66 - 5.89 |
| 52-Week Range | 5.18 - 7.64 |
| Beta | -0.03 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Oct 29, 2026 |
About HKG:0719
Shandong Xinhua Pharmaceutical Company Limited develops, manufactures, and sells bulk pharmaceuticals, preparations, and chemical products in the People’s Republic of China, the Americas, Europe, and internationally. It offers antipyretic and analgesic, cardiovascular and cerebrovascular, anti-infective, and central nervous drugs under the Xinhua brand; and contract manufacturing services for active pharmaceutical ingredients and pharmaceutical intermediates, OTC, and generics. The company also provides ibuprofen bulk pharmaceutical products; a... [Read more]
Financial Performance
In 2025, HKG:0719's revenue was 8.75 billion, an increase of 3.41% compared to the previous year's 8.47 billion. Earnings were 289.89 million, a decrease of -38.32%.
Financial numbers in CNY Financial StatementsNews
Viral dance challenge lifted Chinese ibuprofen maker’s shares – now they are languishing
When an ibuprofen dance challenge went viral on the Chinese social media platform Douyin in late 2022 during the Covid-19 pandemic, shares of the country’s leading ibuprofen maker surged more than 200...